Table 3.
Patient characteristics, Swedish cohort.
| Fingolimod-RR (n = 23) | RRMS (n = 19) | ONDC (n = 20) | HC (n = 5) | |
|---|---|---|---|---|
| M:F | 7:16 | 5:14 | 7:13 | 3:2 |
| Age (years) | 42.4 ± 8.1 | 32.4 ± 8.1 | 34.15 ± 11.1 | 29.8 ± 2.9 |
| EDSS | 3.0 (2.0–3.5) | 2.0 (1.5–3.0) | – | – |
| Disease duration (years) | 10.3 ± 6.1 | 5.89 ± 4.3 | – | – |
| DMT:NODMT | 23:0 | 19:0 | – | – |
All: all subjects; EDSS: Expanded Disability Status Scale; F: female; HC: healthy controls; IQR: interquartile range; M: male; n: number of subjects; ONDC: other neurologic disease controls; RR: relapsing-remitting; RRMS: relapsing-remitting multiple sclerosis; DMT: disease-modifying treatment; NODMT: no use of disease-modifying treatment; SD: standard deviation.
Values are reported as mean ± SD or median (IQR) (Swedish cohort).